CFD 属于复杂的高风险金融工具,其杠杆作用可能导致投资者迅速亏损。 84% 的散户投资者因进行 CFD 交易遭受资金损失。 请您谨慎考虑自己是否了解 CFD 操作,以及是否能够接受高额亏损的风险。

交易 Mersana Therapeutics, Inc. - MRSN CFD

-
0%
  • 概括
  • 历史数据
  • 活动
  • 收入报表
  • 资产负债表
  • 现金流
  • 所有权
交易条件
价差 -
多头隔夜费

Long position overnight fee


Margin. Your investment $1,000.00
隔夜费用 -0.025457 %
Charges from borrowed part ($-1.02)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

前往平台
-0.025457%
空头隔夜费

Short position overnight fee


Margin. Your investment $1,000.00
隔夜费用 0.003235 %
Charges from borrowed part ($0.13)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

前往平台
0.003235%
隔夜费时间 21:00 (UTC)
最小交易量 1
货币 USD
保证金 20%
上市交易所 United States of America
交易费 0%

*Information provided by Capital.com

Mersana Therapeutics Inc ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

关键数据
前收盘价* N/A
开仓* N/A
1 年变化* N/A
日范围* N/A
52 周范围 2.92-8.39
平均交易量(10 天) 1.40M
平均交易量(3 个月) 38.63M
市值 860.18M
市盈率 -100.00K
流通股 114.39M
收入 32.35M
EPS -2.12
股息(收益率 %) N/A
贝塔 1.70
下一个财报发布日期 Aug 7, 2023

所有数据都是由Refinitiv提供的, 除了标有星号的数据, 这是*由 Capital.com 提供的数据

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date 平仓 Change Change (%) 開倉 High Low

Mersana Therapeutics, Inc. Events

时间(协调世界时) (UTC) 国家/地区 事件
Wednesday, June 7, 2023

时间(协调世界时) (UTC)

13:00

国家/地区

US

事件

Mersana Therapeutics Inc at Jefferies Healthcare Conference
Mersana Therapeutics Inc at Jefferies Healthcare Conference

Forecast

-

Previous

-
Thursday, June 8, 2023

时间(协调世界时) (UTC)

14:00

国家/地区

US

事件

Mersana Therapeutics Inc Annual Shareholders Meeting
Mersana Therapeutics Inc Annual Shareholders Meeting

Forecast

-

Previous

-
Friday, June 9, 2023

时间(协调世界时) (UTC)

13:00

国家/地区

US

事件

Mersana Therapeutics Inc Annual Shareholders Meeting
Mersana Therapeutics Inc Annual Shareholders Meeting

Forecast

-

Previous

-
Monday, August 7, 2023

时间(协调世界时) (UTC)

20:00

国家/地区

US

事件

Q2 2023 Mersana Therapeutics Inc Earnings Release
Q2 2023 Mersana Therapeutics Inc Earnings Release

Forecast

-

Previous

-
Monday, November 6, 2023

时间(协调世界时) (UTC)

13:30

国家/地区

US

事件

Q3 2023 Mersana Therapeutics Inc Earnings Release
Q3 2023 Mersana Therapeutics Inc Earnings Release

Forecast

-

Previous

-
查看所有活動
  • 年度
  • 每季度
2022 2021 2020 2019 2018
总收入 26.581 0.043 0.828 42.123 10.594
收入 26.581 0.043 0.828 42.123 10.594
总营业费用 230.348 168.901 88.938 72.323 76.249
销售/一般/行政费用,总计 56.963 36.888 21.902 17.283 16.334
研究与开发 173.385 132.013 67.036 55.04 59.915
Depreciation / Amortization
营业收入 -203.767 -168.858 -88.11 -30.2 -65.655
利息收入(费用),非经营净值 -0.445 -1.202 0.065 1.992 1.398
其他,净值
税前净收入 -204.212 -170.06 -88.045 -28.208 -64.257
税后净收入 -204.212 -170.06 -88.045 -28.208 -64.257
未计算非常项目前的净收益 -204.212 -170.06 -88.045 -28.208 -64.257
净收入 -204.212 -170.06 -88.045 -28.208 -64.257
普通股股东可获收益 (不含非经常性项目) -204.212 -170.06 -88.045 -28.208 -64.257
普通股股东可获收益 (含非經常性項目) -204.212 -170.06 -88.045 -28.208 -64.257
摊薄净收入 -204.212 -170.06 -88.045 -28.208 -64.257
摊薄后加权平均股 93.6542 70.5809 61.4852 43.4921 23.0322
扣除特别项目的每股摊薄盈利 -2.18049 -2.40943 -1.43197 -0.64858 -2.78987
Dividends per Share - Common Stock Primary Issue
每股正常摊薄盈利 -2.18049 -2.40943 -1.43197 -0.64858 -2.78987
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
总收入 7.802 14.688 5.573 4.284 2.036
收入 7.802 14.688 5.573 4.284 2.036
总营业费用 65.603 60.514 65.212 56.034 48.588
销售/一般/行政费用,总计 18.328 14.805 14.573 14.803 12.782
研究与开发 47.275 45.709 50.639 41.231 35.806
营业收入 -57.801 -45.826 -59.639 -51.75 -46.552
利息收入(费用),非经营净值 1.638 0.902 -0.172 -0.469 -0.706
税前净收入 -56.163 -44.924 -59.811 -52.219 -47.258
税后净收入 -56.163 -44.924 -59.811 -52.219 -47.258
未计算非常项目前的净收益 -56.163 -44.924 -59.811 -52.219 -47.258
净收入 -56.163 -44.924 -59.811 -52.219 -47.258
普通股股东可获收益 (不含非经常性项目) -56.163 -44.924 -59.811 -52.219 -47.258
普通股股东可获收益 (含非經常性項目) -56.163 -44.924 -59.811 -52.219 -47.258
摊薄净收入 -56.163 -44.924 -59.811 -52.219 -47.258
摊薄后加权平均股 107.515 101.095 97.6419 95.7568 79.9286
扣除特别项目的每股摊薄盈利 -0.52238 -0.44437 -0.61255 -0.54533 -0.59125
Dividends per Share - Common Stock Primary Issue 0 0 0 0
每股正常摊薄盈利 -0.52238 -0.44437 -0.61255 -0.54533 -0.59125
  • 年度
  • 每季度
2022 2021 2020 2019 2018
流动资产总额 319.219 188.898 258.58 101.326 74.305
现金和短期投资 280.712 177.947 255.094 99.79 70.131
现金等价物 128.885 177.947 255.094 62.351 59.634
应收账款总额,净额 30 0 0.459
Accounts Receivable - Trade, Net 30 0 0.459
Prepaid Expenses 8.507 10.951 3.486 1.536 3.715
Total Assets 334.34 206.111 273.399 107.541 78.502
Property/Plant/Equipment, Total - Net 14.46 14.857 12.666 4.762 2.694
Property/Plant/Equipment, Total - Gross 22.202 22.539 20.301 11.971 9.055
Accumulated Depreciation, Total -7.742 -7.682 -7.635 -7.209 -6.361
Other Long Term Assets, Total 0.661 2.356 2.153 1.453 1.503
Total Current Liabilities 91.533 47.523 30.003 24.07 69.425
Accounts Payable 13.951 12.321 8.34 7.296 10.727
Accrued Expenses 45.982 31.019 17.583 11.205 12.375
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 31.36 3.944 3.987 4.815 46.323
Total Liabilities 242.283 84.37 45.312 29.223 69.707
Total Long Term Debt 25.132 25.075 5.151 4.476 0
Other Liabilities, Total 125.618 11.772 10.158 0.677 0.282
Total Equity 92.057 121.741 228.087 78.318 8.795
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Common Stock 0.011 0.007 0.007 0.005 0.003
Additional Paid-In Capital 746.889 572.213 508.499 270.662 172.966
Retained Earnings (Accumulated Deficit) -654.691 -450.479 -280.419 -192.374 -164.166
Total Liabilities & Shareholders’ Equity 334.34 206.111 273.399 107.541 78.502
Total Common Shares Outstanding 105.145 73.7091 68.8413 45.388 23.2345
短期投资 151.827 0 37.439 10.497
Long Term Investments
Other Equity, Total -0.152 0 0.025 -0.008
Current Port. of LT Debt/Capital Leases 0.24 0.239 0.093 0.754
Long Term Debt 24.929 24.626 4.977 4.201
Capital Lease Obligations 0.203 0.449 0.174 0.275
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
流动资产总额 281.807 319.219 300.037 237.079 241.47
现金和短期投资 273.919 280.712 290.126 225.128 230.057
现金等价物 122.825 128.885 184.082 135.338 230.057
Prepaid Expenses 7.888 8.507 9.911 11.951 11.413
Total Assets 296.195 334.34 314.85 252.351 258.267
Property/Plant/Equipment, Total - Net 13.8 14.46 14.197 14.548 14.55
Other Long Term Assets, Total 0.588 0.661 0.616 0.724 2.247
Total Current Liabilities 83.402 91.533 88.794 71.47 56.463
Accounts Payable 18.156 13.951 13.732 8.158 9.775
Accrued Expenses 35.492 45.982 43.901 36.848 29.879
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 29.754 31.6 31.161 26.464 16.809
Total Liabilities 231.901 242.283 224.621 118.317 117.741
Total Long Term Debt 25.004 24.929 24.853 24.777 24.702
Long Term Debt 25.004 24.929 24.853 24.777 24.702
Other Liabilities, Total 123.495 125.821 110.974 22.07 36.576
Total Equity 64.294 92.057 90.229 134.034 140.526
Common Stock 0.011 0.011 0.01 0.01 0.009
Additional Paid-In Capital 775.125 746.889 700.217 684.106 638.254
Retained Earnings (Accumulated Deficit) -710.854 -654.691 -609.767 -549.956 -497.737
Other Equity, Total 0.012 -0.152 -0.231 -0.126
Total Liabilities & Shareholders’ Equity 296.195 334.34 314.85 252.351 258.267
Total Common Shares Outstanding 109.061 105.145 98.5826 97.1664 87.0731
Property/Plant/Equipment, Total - Gross 22.202
Current Port. of LT Debt/Capital Leases
Preferred Stock - Non Redeemable, Net 0 0 0 0
Accumulated Depreciation, Total -7.742
Capital Lease Obligations
短期投资 151.094 151.827 106.044 89.79
应收账款总额,净额 0 30
Accounts Receivable - Trade, Net 0 30
  • 年度
  • 每季度
2022 2021 2020 2019 2018
净收入/起跑线 -204.212 -170.06 -88.045 -28.208 -64.257
经营活动产生的现金 -49.363 -139.988 -74.696 -67.744 -55.216
经营活动产生的现金 0.927 0.855 1.01 1.245 1.257
非现金物品 20.823 19.132 7.234 4.753 3.718
营运资金的变化 133.099 10.085 5.105 -45.534 4.066
投资活动产生的现金 -152.716 -0.648 37.027 -27.293 87.195
资本支出 -2.197 -0.648 -0.473 -0.605 -1.37
其他投资现金流量项目,总计 -150.519 0 37.5 -26.688 88.565
融资活动产生的现金 153.017 63.646 230.412 97.704 1.064
股票的发行(报废),净额 153.289 2.477 167.689 92.826 1.064
现金净变化 -49.062 -76.99 192.743 2.667 33.043
已付现金利息 2.463 0.429 0.234 0.132
债务的发行(退还),净额 -0.272 61.428 62.723 4.878
融资现金流项目 0 -0.259
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -56.163 -204.212 -159.288 -99.477 -47.258
Cash From Operating Activities -29.005 -49.363 1.866 -52.731 -7.955
Cash From Operating Activities 0.319 0.927 0.645 0.432 0.205
Non-Cash Items 5.148 20.823 16.386 11.11 5.679
Cash Interest Paid 0.791 2.463 1.746 1.1 0.531
Changes in Working Capital 21.691 133.099 144.123 35.204 33.419
Cash From Investing Activities 1.396 -152.716 -107.29 -90.799 -0.329
Capital Expenditures -0.911 -2.197 -1.412 -0.986 -0.329
Other Investing Cash Flow Items, Total 2.307 -150.519 -105.878 -89.813
Cash From Financing Activities 21.549 153.017 111.559 100.921 60.394
Financing Cash Flow Items -0.15 0 0 0 0
Issuance (Retirement) of Stock, Net 21.764 153.289 111.766 101.063 60.47
Issuance (Retirement) of Debt, Net -0.065 -0.272 -0.207 -0.142 -0.076
Net Change in Cash -6.06 -49.062 6.135 -42.609 52.11
投资者名称 投资者类型 流通股百分比 持有股份 股份变动 持有日期 换手率
OrbiMed Advisors, LLC Investment Advisor/Hedge Fund 7.8781 9011437 0 2023-03-31 LOW
Bain Capital Life Sciences Investors, LLC Investment Advisor 7.5741 8663673 0 2023-03-31 LOW
Avoro Capital Advisors LLC Investment Advisor/Hedge Fund 6.6005 7550000 0 2023-03-31 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 5.6058 6412222 556161 2023-03-31 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 5.5956 6400549 15793 2023-03-31 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 4.0377 4618576 189452 2023-03-31 LOW
Bellevue Asset Management AG Investment Advisor 3.7589 4299619 17019 2023-03-31 LOW
Rock Springs Capital Management LP Hedge Fund 3.5877 4103803 0 2023-03-31 LOW
Sarissa Capital Management, L.P. Hedge Fund 3.3221 3800000 -197010 2023-03-31
Avidity Partners Management LP Hedge Fund 3.0015 3433233 3433233 2023-03-31 LOW
Braidwell LP Hedge Fund 2.9338 3355805 1493105 2023-03-31 HIGH
Candriam Belgium S.A. Investment Advisor/Hedge Fund 2.5902 2962848 270000 2023-03-31 LOW
Candriam Luxembourg S.A. Investment Advisor 2.4788 2835409 0 2023-04-30 HIGH
Marshall Wace LLP Investment Advisor/Hedge Fund 2.1827 2496710 -27274 2023-03-31 HIGH
Invus Public Equities Advisors, LLC Investment Advisor 1.9371 2215788 15788 2023-03-31 LOW
Baker Bros. Advisors LP Hedge Fund 1.6489 1886115 1886115 2023-03-31 LOW
D. E. Shaw & Co., L.P. Hedge Fund 1.579 1806099 -529840 2023-03-31 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.5726 1798847 91377 2023-03-31 LOW
Goldman Sachs Asset Management, L.P. Investment Advisor 1.5083 1725328 101999 2023-03-31 LOW
Millennium Management LLC Hedge Fund 1.1025 1261054 -2402473 2023-03-31 HIGH

为什么选择 Capital.com?让我们的数字来说话。

Capital.com Group

535K+

交易者

87K+

每月活跃客户

$113M+

每月投资额

$64M+

每月提取金额

交易计算器

如果您在特定日期(选择一个日期)开立差价合约交易并在不同日期(选择一个日期)关闭交易,计算您的假设盈亏。

交易佣金
0
  • 1:1
杠杆
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
投资
交易规模(杠杆 x 投资):
開倉

平仓

做空 做多

Mersana Therapeutics, Inc. Company profile

关于 Mersana Therapeutics Inc.

Mersana Therapeutics, Inc.是一家处于临床阶段的生物制药公司。 该公司专注于开发抗体药物结合物(ADCs)。 公司的平台包括Dolaflexin和Dolasynthen。 其候选产品包括upifitamab rilsodotin(UpRi,XMT-1536)和XMT-1592。 公司的早期项目包括针对B7-H4的Dolasynthen ADC,XMT-1660,以及利用Immunosynthen平台的候选产品。 UpRi是一种利用公司Dolaflexin平台的ADC,针对NaPi2b,这是一种在卵巢癌和非小细胞肺癌(NSCLC)腺癌中广泛表达的抗原。 XMT-1592采用公司的Dolasynthen平台,靶向NaPi2b。

Industry: Bio Therapeutic Drugs

840 Memorial Dr
CAMBRIDGE
MASSACHUSETTS 02139
US

收入报表

  • Annual
  • Quarterly

人们也观看

BTC/USD

26,982.95 Price
+0.360% 1D Chg, %
多头隔夜费 -0.0616%
空头隔夜费 0.0137%
隔夜费时间 21:00 (UTC)
价差 60.00

US100

14,496.10 Price
+0.270% 1D Chg, %
多头隔夜费 -0.0255%
空头隔夜费 0.0032%
隔夜费时间 21:00 (UTC)
价差 1.8

Gold

1,965.95 Price
-0.690% 1D Chg, %
多头隔夜费 -0.0183%
空头隔夜费 0.0101%
隔夜费时间 21:00 (UTC)
价差 0.30

XRP/USD

0.52 Price
+1.130% 1D Chg, %
多头隔夜费 -0.0753%
空头隔夜费 0.0069%
隔夜费时间 21:00 (UTC)
价差 0.00397

还在找一位您可以信任的经纪商吗?

加入成为全球535,000万多名交易者的一份子,选择利用Capital.com进行交易吧。

1. 创建和验证您的账户 2. 进行存款 3. 找到适合您的交易